Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.
Opinion
Case: 24-1402 Document: 26 Page: 1 Filed: 04/12/2024
NOTE: This order is nonprecedential.
United States Court of Appeals for the Federal Circuit
______________________
REGENERON PHARMACEUTICALS, INC.,
Plaintiff-Appellant v.
MYLAN PHARMACEUTICALS INC., BIOCON
BIOLOGICS INC., Defendants-Cross-Appellants
AMGEN USA, INC., Defendant ______________________ 2024-1402, 2024-1405 ______________________
Appeals from the United States District Court for the Northern District of West Virginia in No. 1:22-cv-00061- TSK-JPM, Chief Judge Thomas S. Kleeh.
______________________
Before CHEN, LINN, and HUGHES, Circuit Judges. PER CURIAM.
ORDER
Following this court’s February 22, 2024 show cause order, the parties agree that the court lacks jurisdiction over both the appeal and cross-appeal from the district court’s December 27, 2023 decision resolving fewer than all Case: 24-1402 Document: 26 Page: 2 Filed: 04/12/2024 2 REGENERON PHARMACEUTICALS, INC. v. MYLAN
PHARMACEUTICALS INC. claims at issue. Under the circumstances, we agree and conclude that dismissal is appropriate.
Accordingly, IT IS ORDERED THAT: (1) Appeal Nos. 2024-1402 and 2024-1405 are dis- missed.
(2) Each party shall bear its own costs.
FOR THE COURT April 12, 2024
Date ISSUED AS A MANDATE: April 12, 2024
Case-law data current through September 30, 2026. Source: CourtListener bulk data.